Stocks · News reference
ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules are the generic version of the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Health Congress 2026 Draws 625+ Leaders From 25 Countries to New York, Names Venture Forum Winners and Announces National and International Expansion
The second annual Global Health Congress convened 625+ healthcare leaders from 25+ countries at the Yale Club of New York City (October 9-11, 2026). The Healthcare Shark Tank competition received 350+ startup applications from 35+ countries, with four winners announced: Stabilis Medical, Florence, Wink, and Braiv. Global Health Forum announced expansion plans for regional chapters across the United States and internationally in India, the United Kingdom, and the Middle East.
8-K filing — ANI PHARMACEUTICALS INC (ANIP)
Filed: 2026-11-05 AccNo: 0001104659-26-123446 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
ANI Pharmaceuticals Announces Recommended Public Offer to Acquire Egetis Therapeutics
ANI Pharmaceuticals has announced a recommended public offer to acquire Swedish biotech company Egetis Therapeutics for SEK 11.25 per share, valuing the transaction at approximately $560 million.
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results and Updates Guidance
ANI Pharmaceuticals reported strong third-quarter 2026 financial results, with revenue of $290.8 million and adjusted non-GAAP EBITDA of $83.3 million, while narrowing its full-year revenue guidance and raising its adjusted EBITDA and EPS outlook.
ANI Pharmaceuticals Announces Participation in Upcoming Investor Conferences
ANI Pharmaceuticals, Inc. announced that its President and CEO, Nikhil Lalwani, and other members of the executive leadership team will participate in investor conferences, including a presentation at the Guggenheim 3rd Annual Healthcare Innovation Conference.